Autifony Therapeutics, a biotechnology company developing novel treatments for serious disorders of the central nervous system, announced that a First-in-Human, randomized, placebo controlled Phase I trial of AUT00201, a potent and selective modulator of Kv3 channels, is underway in the UK.
Kv3 channel dysfunctions have been implicated in a variety of CNS disorders. Autifony’s AUT00201 selectively modulates the function of Kv3 channels and restore normal neuronal function.
The trial has been suspended temporarily in response to the COVID-19 pandemic.
Read more about Autifony Therapeutics here.
Image by Gerd Altmann from Pixabay
